IMV Inc. (IMV): history, ownership, mission, how it works & makes money

A Brief History of IMV Inc. (IMV)

Establishment and Early Years

IMV Inc. was established in 2008, focusing on immuno-oncology and the development of targeted cancer therapies. The company was founded to harness the power of the immune system to improve cancer treatment outcomes.

Public Offering and Growth

In 2016, IMV Inc. went public on the NASDAQ under the ticker symbol IMV. The initial public offering (IPO) raised approximately $10 million at a share price of $5.00. The funding was aimed at advancing the clinical development of its lead product candidates.

Product Development

IMV's lead product candidate, DPX-Survivac, is a therapeutic cancer vaccine targeting various cancers such as ovarian cancer and lymphoma. In 2019, the company reported that DPX-Survivac demonstrated promising results in early-phase clinical trials.

Financial Highlights

As of Q2 2023, IMV reported total assets of approximately $38.3 million, with an accumulated deficit of around $126.7 million since inception. The company had cash and cash equivalents of $30.1 million, which was expected to fund operations into 2024.

Recent Milestones

In September 2022, IMV presented data from its Phase 2 clinical trial for combination therapy involving DPX-Survivac and other agents. The results showed a notable increase in overall response rates among participants.

Market Performance

As of October 2023, IMV's stock price is approximately $1.20 per share, reflecting a market capitalization of around $70 million. Over the past year, the stock has experienced volatility with a high of $2.50 and a low of $0.90.

Table of Financial Performance

Strategic Collaborations

IMV has engaged in strategic partnerships to enhance its research capabilities. Notably, in 2021, the company entered a collaboration agreement with Merck KGaA for the development of novel immune-oncology therapies.

Future Outlook

With ongoing clinical trials and potential new partnerships, IMV aims to expand its product pipeline and improve its market position in the immunotherapy landscape. The focus remains on achieving milestones that can drive future revenues and increase shareholder value.

A Who Owns IMV Inc. (IMV)

Ownership Structure

IMV Inc. (IMV) is a publicly traded biotechnology company specializing in immunotherapy for cancer and infectious diseases. As of the latest available data in October 2023, the ownership structure of IMV Inc. is as follows:

Top Institutional Investors

The following are some of the top institutional investors holding significant stakes in IMV Inc. as of the third quarter of 2023:

Insider Ownership

As of October 2023, the following key executives and board members own shares in IMV Inc.

Market Capitalization

The market capitalization of IMV Inc. is a critical indicator of its size and valuation in the market. As of the end of September 2023, the market cap of IMV is:

Recent Share Price Performance

IMV's share price has shown notable fluctuations over the past year. The following details summarize its performance:

Recent Financial Performance

IMV Inc.’s recent financial performance is reflected in its quarterly results, which include revenues and expenses:

Conclusion on Ownership Trends

The current ownership trends indicate a significant presence of institutional investors, alongside a growing interest from retail investors. The management team also holds a notable stake, demonstrating their alignment with shareholder interests.

IMV Inc. (IMV) Mission Statement

Mission Overview

The mission of IMV Inc. is to advance the field of cancer immunotherapy by developing its proprietary platform, which is designed to stimulate and enhance the immune system's ability to fight cancer. IMV is committed to bringing innovative treatments to patients with unmet medical needs.

Core Values

• Innovation: Commitment to developing cutting-edge therapies.
• Collaboration: Partnering with leading research institutions and healthcare organizations.
• Integrity: Adhering to the highest ethical standards in all practices.
• Patient-Centricity: Focusing on the needs and experiences of patients.

Business Objectives

• To initiate clinical trials for its lead product candidate, MVP-S, targeting multiple cancers.
• To expand its research into additional therapeutic areas beyond oncology.
• To establish strategic collaborations to enhance its product pipeline.
• To achieve regulatory approvals for its therapies by targeting key markets including the U.S. and Europe.

Latest Financial Performance

As of Q3 2023, IMV Inc. reported the following financial data:

Clinical Developments

IMV is focused on advancing its lead clinical candidates through various stages of development. The latest data include:

Regulatory Environment

IMV Inc. is actively working within the regulatory frameworks established by the FDA and EMA. The company is committed to ensuring compliance with all necessary guidelines to facilitate the approval of its therapies.

Market Positioning

As a player in the biotech sector, IMV operates in a competitive landscape. In 2023, the global cancer immunotherapy market is valued at approximately £130 billion and is expected to grow at a CAGR of 12% through 2027. IMV aims to capture market share through its innovative treatment approaches and successful clinical outcomes.

How IMV Inc. (IMV) Works

Business Model

IMV Inc. operates primarily in the biotechnology sector, focusing on the development of innovative immunotherapies for cancer. The company utilizes its proprietary DPX platform to create treatments that harness the body's immune system to target and fight cancer cells.

Products and Pipeline

The company has a diversified pipeline of product candidates targeting various types of cancer. As of October 2023, IMV's lead product is DPX-Survivac, an immunotherapy designed for patients with advanced ovarian cancer. Other notable candidates include:

• DPX-001: A candidate for patients with various solid tumors.
• DPX-Ac2: Targeting HPV-related cancers.
• Combination therapies with checkpoint inhibitors.

Market Strategy

IMV Inc. positions itself in the market by focusing on partnerships with larger pharmaceutical companies for co-development and commercialization. This strategy aims to leverage the expertise and resources of established players in the industry.

Financial Metrics

In the fiscal year ended December 31, 2022, IMV reported:

• Total revenue of $1.2 million.
• Net loss of $28.4 million.
• Research and development expenses of $24 million.
• General and administrative expenses of $4.4 million.

Funding and Investments

IMV Inc. has raised significant capital through various funding rounds. As of 2023, the total amount raised in its latest funding round was $50 million, which is intended to support clinical trials and research initiatives.

Stock Performance

As of October 2023, IMV Inc. trades on the NASDAQ under the ticker symbol IMV.

Collaborations and Partnerships

IMV has established various collaborations to enhance its research capabilities. Specific partnerships include:

• Collaboration with Merck for combined therapy trials.
• Alliances with academic institutions for research advancements.
• Partnerships with contract research organizations for clinical trial management.

Regulatory Approvals

IMV has submitted applications for regulatory approvals for its lead product candidate. As of October 2023, IMV has received:

• Orphan Drug Designation from the FDA for DPX-Survivac.
• Fast Track designation for a subset of patients.

Recent Developments

Recent developments in IMV's operational framework include:

• Initiation of Phase 2 clinical trials for DPX-Survivac.
• Expansion of research teams to enhance clinical development capabilities.
• Increased patient enrollment in ongoing studies.

Future Outlook

IMV is focused on advancing its clinical pipeline and seeking new opportunities for partnerships. The company aims to expand its market presence in the oncology sector by leveraging its cutting-edge technology and innovative therapies.

How IMV Inc. (IMV) Makes Money

Revenue Streams

IMV Inc. primarily generates revenue through its therapeutic product candidates and collaborations with other pharmaceutical companies. As of 2022, the company reported total revenues of approximately $2.7 million, which included revenue from government grants and collaboration agreements.

Product Development and Sales

IMV focuses on the development of its lead product candidate, DPX-Survivac, for the treatment of various cancers. In 2023, the company projected an increase in revenue as clinical trials progressed. The estimated market size for ovarian cancer treatments in the United States is projected to reach $1.8 billion by 2025.

Collaboration Agreements

Through strategic partnerships, IMV has entered into several collaboration agreements with larger pharmaceutical companies. In 2021, IMV signed a collaboration deal with Merck to evaluate the combination of DPX-Survivac with Merck's Keytruda. This partnership includes milestone payments that can add substantially to IMV’s revenue.

Government Grants and Funding

IMV has benefited from various grants aimed at supporting cancer research and immunotherapy. For instance, in 2020, the company received a $1.5 million grant from the National Cancer Institute (NCI) to advance its clinical studies. Similar grants have been critical to funding operations.

Market Potential and Future Outlook

The global cancer immunotherapy market is expected to reach approximately $115 billion by 2028, growing at a CAGR of about 14.5%. IMV aims to capitalize on this growth by advancing its pipeline and expanding its strategic partnerships.

Stock Performance and Investor Relations

As of October 2023, IMV Inc. had a market capitalization of approximately $60 million. Stock price performance is influenced by clinical trial results and announcements regarding partnerships or funding. Investors closely monitor these indicators to gauge the company’s potential for profitability.

Conclusion

IMV Inc. is strategically positioned within the therapeutic landscape with multiple revenue streams, including product sales, collaborations, and grants. Continued advancements in clinical trials and market expansion are critical for the company’s financial progression.